Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis
- Authors
- Lee, Young Ho; Bae, Sang-Cheol
- Issue Date
- Jun-2016
- Publisher
- SPRINGER HEIDELBERG
- Keywords
- Rheumatoid arthritis; TNF blockers; PTPRC; FCGR polymorphism; Responsiveness
- Citation
- RHEUMATOLOGY INTERNATIONAL, v.36, no.6, pp.837 - 844
- Indexed
- SCIE
SCOPUS
- Journal Title
- RHEUMATOLOGY INTERNATIONAL
- Volume
- 36
- Number
- 6
- Start Page
- 837
- End Page
- 844
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5029
- DOI
- 10.1007/s00296-016-3476-5
- ISSN
- 0172-8172
- Abstract
- We aimed to investigate whether the PTPRC rs10919563 A/G and Fc gamma receptor 2A (FCGR2A) R131H polymorphisms can predict the response to anti-TNF therapy in rheumatoid arthritis (RA) patients. We conducted a meta-analysis of studies on the association between the PTPRC rs10919563 A/G or the FCGR2A R131H polymorphism and responsiveness to anti-TNF therapy in RA patients. Eighteen studies (twelve on PTPRC and six on FCGR2A) from eight articles involving 3058 patients were considered in this meta-analysis. The meta-analysis showed a significant association between the PTPRC rs10919563 A allele and response to TNF-α blockers in RA. The OR of the PTPRC A allele was significantly lower in responders (OR = 0.584, 95 % CI = 0.409–0.835, P = 0.003). Meta-analysis revealed no association between the FCGR2A HH + HR genotype and responsiveness to TNF blockers in all study subjects (OR = 0.762, 95 % CI = 0.543–1.068, P = 0.115). However, stratification by TNF inhibitor type showed that the FCGR2A HH + HR genotype was associated with responsiveness to adalimumab (OR = 0.591, 95 % CI = 0.369–0.947, P = 0.029), but not infliximab and etanercept (OR = 0.929, 95 % CI = 0.354–2.440, P = 0.881; OR = 0.804, 95 % CI = 0.293–2.207, P = 0.673). The PTPRC rs10919563 A allele shows a poor response to anti-TNF therapy, and the FCGR2A HH + HR genotype shows a poor response to adalimumab for RA. Genotyping for these polymorphisms may be useful for predicting the response to TNF-α blockers with respect to personalized medicine.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5029)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.